A Cohort Study of SGLT-2 Gliflozins and its Effect on Glycaemic Index in CHF Patients With and Without Diabetes

Background: Although there are many treatment options available, SGLT-2 inhibitors are emerging as effective agents in the treatment of congestive heart failure (CHF) patients with and without diabetes. This study aims to measure the glycaemic index maintained by Dapagliflozin in CHF patients with and without diabetes. Materials and Methods: A 12-months cohort study was conducted in tertiary care hospital. The study included 150 participants diagnosed with CHF and based on the study criteria. Data collected from patient records and lab data were analysed by Student t-test. Results: The overall difference in means of FBS, PPBS and HbA1C between the two groups were statistically significant with a p-value of 0.0067, 0.0034, 0.0046 (p value<0.05, 95% confidence interval) with no hypoglycaemic episodes and other adverse effects. Conclusion: Thus, our study highlights the importance of stable glycemic index managed by SGLT2 inhibitor Dapagliflozin with negligible hypoglycemic effects posing a positive outcome in CHF patients with and without diabetes.